Diacylglycerol lipase-alpha (DAGLA)

The protein contains 1042 amino acids for an estimated molecular weight of 114952 Da.

 

Serine hydrolase that hydrolyzes arachidonic acid-esterified diacylglycerols (DAGs) to produce the principal endocannabinoid, 2-arachidonoylglycerol (2-AG) (PubMed:14610053, PubMed:26668358, PubMed:23502535). Preferentially hydrolyzes sn-1 fatty acids from diacylglycerols (DAG) that contain arachidonic acid (AA) esterified at the sn-2 position to biosynthesize 2-AG (PubMed:14610053, PubMed:26668358, PubMed:23502535). Has negligible activity against other lipids including monoacylglycerols and phospholipids (PubMed:14610053). Plays a key role in regulating 2-AG signaling in the central nervous system (CNS). Regulates 2-AG involved in retrograde suppression at central synapses. Supports axonal growth during development and adult neurogenesis. Plays a role for eCB signaling in the physiological regulation of anxiety and depressive behaviors. Regulates also neuroinflammatory responses in the brain, in particular, LPS-induced microglial activation (By similarity). (updated: Aug. 12, 2020)

Protein identification was indicated in the following studies:

  1. Bryk and co-workers. (2017) Quantitative Analysis of Human Red Blood Cell Proteome. J Proteome Res. 16(8), 2752-2761.

Methods

The following articles were analysed to gather the proteome content of erythrocytes.

The gene or protein list provided in the studies were processed using the ID mapping API of Uniprot in September 2018. The number of proteins identified and mapped without ambiguity in these studies is indicated below.
Only Swiss-Prot entries (reviewed) were considered for protein evidence assignation.

PublicationIdentification 1Uniprot mapping 2Not mapped /
Obsolete
TrEMBLSwiss-Prot
Goodman (2013)2289 (gene list)227853205992269
Lange (2014)123412347281224
Hegedus (2015)2638262202352387
Wilson (2016)165815281702911068
d'Alessandro (2017)18261817201815
Bryk (2017)20902060101081942
Chu (2018)18531804553621387

1 as available in the article and/or in supplementary material
2 uniprot mapping returns all protein isoforms as one entry

The compilation of older studies can be retrieved from the Red Blood Cell Collection database.

The data and differentiation stages presented below come from the proteomic study and analysis performed by our partners of the GReX consortium, more details are available in their published work.

No sequence conservation computed yet.

This protein is annotated as membranous in Gene Ontology, is annotated as membranous in UniProt, is predicted to be membranous by TOPCONS.


Interpro domains
Total structural coverage: 0%
Model score: 0
No model available.

(right-click above to access to more options from the contextual menu)

VariantDescription
dbSNP:rs35056845
dbSNP:rs3741252
dbSNP:rs34956386

No binding partner found

The reference OMIM entry for this protein is 608687

Spinocerebellar ataxia 20; sca20
Chromosome 11q12 duplication syndrome, 260-kb
Spinocerebellar ataxia with dysphonia
Spinocerebellar ataxia with spasmodic cough

A number sign (#) is used with this entry because spinocerebellar ataxia-20 (SCA20) is caused by a heterozygous 260-kb duplication on chromosome 11q12, and is thus a contiguous gene duplication syndrome.

DESCRIPTION

SCA20 is an autosomal dominant adult-onset disorder characterized by dysarthria due to spasmodic dysphonia followed by slowly progressive ataxia (summary by Knight et al., 2004). For a general discussion of autosomal dominant spinocerebellar ataxia, see SCA1 (164400).

CLINICAL FEATURES

Knight et al. (2004) reported a family of Anglo-Celtic origin with a relatively pure form of autosomal dominant spinocerebellar ataxia. Fourteen affected members were examined. The age at onset ranged from 19 to 64 years (mean and median both 46.5 years), with an average 10-year earlier onset in the children of affected parents. The most common presenting symptom was dysarthria (in 9 of 14 patients) due to spasmodic dysphonia, which was not associated with laryngeal muscle paralysis. Dysarthria and dysphonia were followed by gait ataxia in 7 patients and upper limb ataxia in 2. There was slow disease progression, with only 1 affected member becoming wheelchair-dependent after 40 years of symptoms. Other variable features included mild pyramidal signs, hypermetric saccades, and mild nystagmus. Palatal tremor or myoclonus was apparent in 10 patients. CT scan showed pronounced dentate calcification in 9 of 9 patients who were imaged. Direct testing for CAG and ATTCT repeat expansions was negative. Coutinho et al. (2006) reported 6 Portuguese families in which a total of 19 individuals were affected with autosomal dominant spinocerebellar ataxia and spasmodic coughing episodes. Paroxysmal coughing attacks first occurred at 25 to 55 years of age, whereas signs of cerebellar ataxia developed later at 40 to 65 years of age. In most patients, the coughing came in bursts without clear precipitating factors, occurred daily, and lasted several minutes. The coughing episodes tended to decrease in frequency and severity with age and after the onset of cerebellar ataxia. There was no evidence of respiratory diseases, allergies, or gastric complaints. Ten patients with long-standing disease had downbeat nystagmus, and 1 patient had dentate calcifications. Coutinho et al. (2006) suggested that the disorder in these families may be similar to that reported by Knight et al. (2004) and may result from dysfunction of cerebellar neural networks that influence breathing and coughing reflexes.

MAPPING

Genomewide linkage analysis of the family reported by Knight et al. (2004) identified a disease locus, designated SCA20, in a pericentromeric region on chromosome 11 (lod score of 4.47 at marker D11S4191). Haplotype analysis defined a 25.4-Mb interval between markers D11S903 and FGF3 (164950). Knight et al. (2004) noted that the SCA20 candidate region overlaps with that of SCA5 (600224). Lorenzo et al. (2006) refined the SCA20 candidate region to a 23.6-Mb interval between D11S903 and KAD199. Although the SPTBN2 gene (604985), responsible for SCA5, maps within the SCA20 region, detailed molecular analysis in an affected member of the original SCA20 family (Knight et al., 2004) revealed no pathogenic mutations. Lorenzo et al. (2006) concluded that SCA20 and SCA5 are genetically distinct disorders.

CYTOGENETICS

In affected members of the family with SCA20 reported by Knight et al. (2004), Knight et al. (2008) identified a heter ... More on the omim web site

Subscribe to this protein entry history

Aug. 24, 2020: Protein entry updated
Automatic update: Entry updated from uniprot information.

June 30, 2020: Protein entry updated
Automatic update: OMIM entry 608687 was added.

Oct. 19, 2018: Additional information
Initial protein addition to the database. This entry was referenced in Bryk and co-workers. (2017).